AZ sheds Nexium, Vimovo rights to Gruenenthal
AstraZeneca is continuing to shed products outside the scope of its three core therapy areas with the sale of certain rights to Nexium and Vimovo to Grünenthal.
Read More
Tag: Gruenenthal
Gruenenthal launches PhIII trials of neridronate for rare pain disorder
Gruenenthal has kicked off two pivotal Phase III trials investigating the bisphosphonate neridronate for the treatment of Complex Regional Pain Syndrome (CRPS).
Read More
NICE rejects Zurampic for hyperuricaemia in gout patients
Cost regulators for the NHS in England and Wales have published draft guidelines barring adults with gout from routine access to Gruenenthal’s Zurampic-based therapy for treating hyperuricaemia.
Read More
Five pharmas fall foul of ABPI Code of Practice
A stream of breaches of the Association of the British Pharmaceutical Industry’s Code of Practice has seen five pharmaceutical companies – AstraZeneca, Gruenenthal, Janssen-Cilag, Boehringer Ingelheim and Eli Lilly – named and shamed in the British medical press.
Read More
- Bioxytran reports positive phase 1b/2a results for antiviral ProLectin‑M
- FDA approves once‑weekly Sogroya for wider paediatric use
- SolasCure trial shows faster healing with Aurase Wound Gel
- Gilead data show investigational HIV combination maintains viral suppression
- Verdiva Bio completes enrolment for phase 2b study of oral GLP‑1 candidate VRB‑101
